In addition,Albitar et al. (34) demonstrated a high level of soluble CD52in the plasma of patients which is inversely associated withthe plasma concentration of Alemtuzumab and also can causea nearly 4-fold increase in the risk of death in CLL patients.Therefore, the presence of MVs bearing CD52 could be apoor prognostic biomarker for the CLL progression towardthe advanced stage. Here, CD52 is linked to B-cell chronic lymphocytic leukemia.